Pharma Equity Group A/S (BLVIS A) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Realty

Market cap

DKK 143 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-999,999.00

Return on Equity

-62.02%

Price to Book

3.63

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2024)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-30.27%

6 Months

-5.09%

1 Year

-39.71%

2 Years

-75.83%

3 Years

-86.86%

4 Years

-91.53%

5 Years

-88.95%

Pharma Equity Group A/S for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

-2.47

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

6.92%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

2.49%

ROE (avg)

4.96%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.15

EV to EBIT

-6.66

EV to EBITDA

-6.73

EV to Capital Employed

2.48

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-37.26%

ROE (Latest)

-62.02%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Pharma Equity Group A/S"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -0.41% vs -794.29% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.10",
          "val2": "-24.80",
          "chgp": "14.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.00",
          "val2": "1.60",
          "chgp": "212.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.40",
          "val2": "-24.30",
          "chgp": "-0.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-21.10

-24.80

14.92%

Interest

5.00

1.60

212.50%

Exceptional Items

0.00

Consolidate Net Profit

-24.40

-24.30

-0.41%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -0.41% vs -794.29% in Dec 2023

All Annual Results

Company CV

About Pharma Equity Group A/S

Pharma Equity Group A/S

Realty

Blue Vision A/S, formerly Gudme Raaschou Vision A/S, is a Denmark-based company engaged in the investment in and development of real estate. The Company’s strategy comprises investment and development of both residential and commercial real estate properties with intention of subsequent sale. It primarily focuses on domestic real estate properties located in Denmark and Southern Sweden. The Company’s property portfolio includes such properties, as Mikkelborg Park in Hoersholm and Roret in Snekkersten, among others. The Company's major shareholder is Kiwi Deposit Holding A/S, which owns approximately 45% shares. The Company has one direct wholly owned subsidiaries, namely Seaside Holding A/S, as well as a number of indirectly owned subsidiaries, including Mikkelborg Park Holding ApS, Roret Snekkersten ApS and Skovgaardsvejd Holding ApS, among others. In July 2013, it divested its subsidiary Strandpromenaden A/S.

Company Coordinates

Company Details

Vester Farimagsgade 1, 2. , KOEBENHAVN V None : 1606

Tel: 45 36 944417

http://www.blue-vision.dk/

Registrar Details